MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Government: International
North America
United States of America
Government: U.S. States & Territories
Government: States (U.S.)
Missouri
Industry: Missouri
C2N Diagnostics, LLC (C2N)
Organization & Developments: C2N Diagnostics
Parents
C2N Diagnostics, LLC (C2N)
Children
2021: C2N Diagnostics_Fierce 15
2025: FDA greenlights first blood test to diagnose Alzheimer's disease
C2N Diagnostics is looking to make the diagnosis of Alzheimer’s disease easier with its non-invasive blood test.
C2N Diagnostics, LLC is a protein diagnostic and therapeutic discovery company targeting progressive neurodegeneration.
The test uses mass spectrometry to measure the amounts of certain amyloid-β peptides floating in the bloodstream, as well as versions of the fat-binding protein apolipoprotein E, a common risk factor for Alzheimer’s.
They reside at the Center for Emerging Technologies in St. Louis.
Jumps
*Key People: C2N Diagnostics
Finance & Acquisitions: C2N Diagnostics